Key facts
- Cytotheryx’s last known valuation is $140.0M (Jan 2026).
- It has raised $26.5M; the latest was Later Stage VC ($60.0M) in Jan 2026.
- Notable investors include Mayo Clinic, Austin Area Angels, Children's Minnesota, FIN Capital Angels, Hill Capital Corporation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cytotheryx
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytotheryx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytotheryx
Developer of a therapeutic platform designed to develop cell-based therapies for acute, chronic, and rare liver diseases. The company offers a proprietary bio-incubator that produces scalable, clinically relevant primary human hepatocytes and supports programs in bioartificial liver assist devices, hepatocyte-cell transplant therapy, hepatitis research, gene therapy testing, and preclinical safety and toxicology testing, enabling researchers and healthcare providers to advance effective treatments for liver-related conditions.
- Sector
- Healthcare
- HQ
- Rochester, MN, United States
- Founded
- 2018
- Employees
- 15
- Website
- cytotheryx.com/
- Ownership
- Privately Held (backing)
Cytotheryx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytotheryx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytotheryx in its N-PORT filings yet. We sweep new filings monthly.